Last reviewed · How we verify
NCT03971305
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
trial in MRD in 300 participants. Status unknown.
5 May 2022
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 5 May 2017 |
| Primary completion | 5 May 2022 |
| Estimated completion | 5 May 2025 |
| Sites | 1 location across China |
Conditions studied
- MRD — all drugs for MRD →
- MDD — all drugs for MDD →
- Lymphoma, Nonhodgkin — all drugs for Lymphoma, Nonhodgkin →
- Anaplastic Lymphoma — all drugs for Anaplastic Lymphoma →
Sponsor
Sun Yat-sen University
Who can join
Adults 1 to 18, any sex, with MRD or MDD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Studies in Germany and the United States have shown that pathological types of systemic anaplastic large cell lymphoma (ALCL) in children and adolescents, minimal disseminated disease (MDD) in peripheral blood or bone marrow and minimal residual disease (MRD) are significantly associated with prognosis, suggesting that these factors need to be combined in risk stratification of ALCL patients. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. We adjusted the original NHL-BFM-90/95 regimen, mainly in the aspects of clinical staging, efficacy evaluation, risk stratification and treatment regimen，etc.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study.
Chen T, Zeng C, Wang J, Sun F, et al · · 2024 · cited 2× · PMID 38810968 · DOI 10.4143/crt.2024.104 -
Advances and updates in pediatric anaplastic large cell lymphoma.
Marks LJ, Lowe E, Kamdar K. · · 2025 · PMID 40690755 · DOI 10.1182/bloodadvances.2025015935
Verify or expand the search:
- PubMed search for NCT03971305
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for MRD
Currently open trials in the same condition.
- NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
- NCT06409702 — Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection · Phase 4 · recruiting
- NCT06918262 — Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer · recruiting
- NCT05736978 — Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results · Phase 2 · recruiting
- NCT05536505 — Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC · Phase 2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03971305 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 9 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03971305.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing